Journal of Hematology & Oncology

Table 3 Univariate and multivariate regression models of OS, EFS, and RR

From: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

	OS						EFS							RR
	n	HR			95 % CI	P value	n	HR	95 % CI			P value		n	HR	95 % CI			P value
Univariable model
MEF2C Expression
Low (Q1–3)	563	1					563	1						430	1
High (Q4)	188	1.385			1.07–1.80	0.014	188	1.510	1.21–1.88			<0.001		126	1.813	1.36–2.42			<0.001
Disease risk^a
Standard-risk	353	1					353	1						254	1
Low-risk	284	0.351			0.26–0.48	<0.001	284	0.440	0.34–0.56			<0.001		234	0.410	0.30–0.56			<0.001
High-risk	99	1.234			0.90–1.69	0.193	99	1.377	1.05–1.81			0.022		57	0.886	0.59–1.34			0.567
FAB Class
Not M0	624	1					624	1						471	1
M0	19	2.847			1.62–5.00	<0.001	19	2.192	1.33–3.63			0.002		11	2.641	1.33–5.24			0.006
Multivariable model^b
MEF2C Expression
Low (Q1–3)	477	1					477	1						371	1
High (Q4)	152	0.986			0.72–1.36	0.929	152	1.135	0.86–1.49			0.365		101	1.324	0.91–1.92			0.137
Disease risk^a
Standard-risk	292	1					292	1						213	1
Low-risk	252	0.330			0.23–0.48	<0.001	252	0.419	0.31–0.56			<0.001		210	0.422	0.30–0.59			<0.001
High-risk	85	1.251			0.85–1.78	0.214	85	1.275	0.90–1.75			0.180		49	0.872	0.56–1.36			0.549
FAB Class
Not M0	610	1					610	1						461	1
M0	19	1.981			1.09–3.59	0.024	19	2.382	1.05–5.42			0.038		11	1.646	0.78–3.45			0.187

^aSee “Methods” section for definition of cytogenetic/molecular disease risk
^bModels were also adjusted for treatment arm, FAB category (M0 vs. no-M0), and age

Back to article page

ISSN: 1756-8722

Contact us

General enquiries: journalsubmissions@springernature.com